New drug combo aims to boost Last-Resort cancer treatment
NCT ID NCT06854159
Summary
This study is testing whether adding a new drug called odronextamab can improve the effectiveness of a powerful last-resort treatment (CAR-T therapy) for an aggressive type of blood cancer called DLBCL. The trial is for adults whose cancer has come back or hasn't responded to at least two prior treatments. Researchers want to see if giving the new drug before and after the CAR-T therapy helps patients respond better and stay in remission longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California Davis Comprehensive Cancer Center
RECRUITINGSacramento, California, 95817, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.